CONTEXT: - Invasive pancreatic ductal adenocarcinoma has a greater than 90% mortality rate at 5 years. Understanding noninvasive, curable precursor lesions gives us the best hope for reducing mortality from pancreatic ductal adenocarcinoma. The 3 pancreatic precursor lesions that have been well studied include intraductal papillary mucinous neoplasm, mucinous cystic neoplasm, and pancreatic intraepithelial neoplasia. OBJECTIVE: - To give an update on the latest clinical, molecular, and pathologic advances in intraductal papillary mucinous neoplasm, mucinous cystic neoplasm, and pancreatic intraepithelial neoplasia for the general surgical pathologist. DATA SOURCES: - The current literature was analyzed and the authors' experiences with institutional and consult material were incorporated. CONCLUSIONS: - Our understanding of the molecular alterations that lead from pancreatic precursor lesion to invasive carcinoma continues to evolve. These advances aid clinicians in their treatment decisions and researchers in their search for actionable, druggable targets.
CONTEXT: - Invasive pancreatic ductal adenocarcinoma has a greater than 90% mortality rate at 5 years. Understanding noninvasive, curable precursor lesions gives us the best hope for reducing mortality from pancreatic ductal adenocarcinoma. The 3 pancreatic precursor lesions that have been well studied include intraductal papillary mucinous neoplasm, mucinous cystic neoplasm, and pancreatic intraepithelial neoplasia. OBJECTIVE: - To give an update on the latest clinical, molecular, and pathologic advances in intraductal papillary mucinous neoplasm, mucinous cystic neoplasm, and pancreatic intraepithelial neoplasia for the general surgical pathologist. DATA SOURCES: - The current literature was analyzed and the authors' experiences with institutional and consult material were incorporated. CONCLUSIONS: - Our understanding of the molecular alterations that lead from pancreatic precursor lesion to invasive carcinoma continues to evolve. These advances aid clinicians in their treatment decisions and researchers in their search for actionable, druggable targets.
Authors: Catherine G Fischer; Violeta Beleva Guthrie; Alicia M Braxton; Lily Zheng; Pei Wang; Qianqian Song; James F Griffin; Peter E Chianchiano; Waki Hosoda; Noushin Niknafs; Simeon Springer; Marco Dal Molin; David Masica; Robert B Scharpf; Elizabeth D Thompson; Jin He; Christopher L Wolfgang; Ralph H Hruban; Nicholas J Roberts; Anne Marie Lennon; Yuchen Jiao; Rachel Karchin; Laura D Wood Journal: Gastroenterology Date: 2019-06-05 Impact factor: 22.682
Authors: Michael Skaro; Neha Nanda; Christian Gauthier; Matthäus Felsenstein; Zhengdong Jiang; Miaozhen Qiu; Koji Shindo; Jun Yu; Danielle Hutchings; Ammar A Javed; Ross Beckman; Jin He; Christopher L Wolfgang; Elizabeth Thompson; Ralph H Hruban; Alison P Klein; Michael Goggins; Laura D Wood; Nicholas J Roberts Journal: Gastroenterology Date: 2019-02-01 Impact factor: 22.682
Authors: Elizabeth M Hecht; Gaurav Khatri; Desiree Morgan; Stella Kang; Priya R Bhosale; Isaac R Francis; Namita S Gandhi; David M Hough; Chenchan Huang; Lyndon Luk; Alec Megibow; Justin M Ream; Dushyant Sahani; Vahid Yaghmai; Atif Zaheer; Ravi Kaza Journal: Abdom Radiol (NY) Date: 2020-11-13
Authors: Kohei Fujikura; Zainab I Alruwaii; Michael C Haffner; Maria A Trujillo; Nicholas J Roberts; Seung-Mo Hong; Anne Macgregor-Das; Michael G Goggins; Sujayita Roy; Alan K Meeker; Ding Ding; Michael Wright; Jin He; Ralph H Hruban; Laura D Wood Journal: J Pathol Date: 2021-05-21 Impact factor: 9.883
Authors: Ying Liu; Sukhwinder Kaur; Ying Huang; Johannes F Fahrmann; Jo Ann Rinaudo; Samir M Hanash; Surinder K Batra; Aatur D Singhi; Randall E Brand; Anirban Maitra; Brian B Haab Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-06-12 Impact factor: 4.254